Study of Mantle Cell Lymphoma Treatment by RiBVD
NCT01457144
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
76
Enrollment
OTHER
Sponsor class
Conditions
Mantle Cell Lymphoma
Interventions
DRUG:
RiBVD
Sponsor
French Innovative Leukemia Organisation
Collaborators
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]